Analyst Price Targets — CABA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 21, 2024 12:41 pm | Ben Burnett | Stifel Nicolaus | $32.00 | $17.54 | StreetInsider | Cabaletta Bio Inc. (CABA) PT Raised to $32 at Stifel |
| January 3, 2023 9:04 am | — | Wells Fargo | $14.00 | $9.30 | Benzinga | Wells Fargo Maintains Overweight on Cabaletta Bio, Raises Price Target to $14 |
| August 30, 2022 4:59 am | Michael Ulz | Morgan Stanley | $3.00 | $1.26 | TheFly | Cabaletta Bio downgraded to Equal Weight from Overweight at Morgan Stanley |
Latest News for CABA
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds…
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CABA.
U.S. House Trading
No House trades found for CABA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.